Back to Newsroom
Back to Newsroom

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of PYX, TEVA and FDX

Friday, 12 July 2019 03:45 PM

The Klein Law Firm

Topic:
5

NEW YORK, NY / ACCESSWIRE / July 12, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Pyxus International, Inc. (NYSE: PYX)
Class Period: on behalf of stockholders who purchased Pyxus (f/k/a Alliance One International, Inc. (AOI)) securities between June 7, 2018 and November 8, 2018, inclusive.
Lead Plaintiff Deadline: August 6, 2019

The complaint alleges that throughout the class period Pyxus International, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing longer shipping cycles; (2) as a result, the Company’s financial results would be materially affected; (3) the Company lacked adequate internal control over financial reporting; (4) the Company’s accounting policies were reasonably likely to lead to regulatory scrutiny; and (5) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Get additional information about the PYX lawsuit: http://www.kleinstocklaw.com/pslra-1/pyxus-international-inc-f-k-a-alliance-one-international-inc-loss-submission-form?id=2375&from=1

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA)
Class Period: on behalf of all persons or entities who purchased or otherwise acquired Teva American Depositary Shares (“ADS”) between August 4, 2017 and May 10, 2019
Lead Plaintiff Deadline: August 23, 2019

During the class period, Teva Pharmaceutical Industries Ltd. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) contrary to its public denials, Teva had in fact engaged in a vast, industry-wide price-fixing scheme and other collusive misconduct since at least 2012; (ii) Teva was not only a participant, but the company at the heart of the anticompetitive scheme; and (iii) several Teva employees had such deep involvement in the scheme that they would ultimately be named personally as defendants in a sweeping civil enforcement action filed by the AGs of virtually every state in the nation.

Get additional information about the TEVA lawsuit: http://www.kleinstocklaw.com/pslra-1/teva-pharmaceutical-industries-ltd-loss-submission-form?id=2375&from=1

FedEx Corporation (NYSE: FDX)
Class Period: September 19, 2017 to December 18, 2018
Lead Plaintiff Deadline: August 26, 2019

The complaint alleges that during the class period FedEx Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) TNT’s overall package volume growth was slowing as TNT’s large customers permanently took their business to competitors after the Cyberattack; (2) as a result of the customer attrition, TNT was experiencing an increased shift in product mix from higher-margin parcel services to lower-margin freight services; (3) the anticipated costs and timeframe to integrate and restore the TNT network were significantly larger and longer than disclosed; (4) FedEx was not on track to achieve TNT synergy targets; and (5) as a result of these undisclosed negative trends and cost issues, FedEx’s positive statements about TNT’s recovery from the Cyberattack, integration into FedEx’s legacy operations, customer mix, customer service levels, profitability, and prospects lacked a reasonable basis.

Get additional information about the FDX lawsuit: http://www.kleinstocklaw.com/pslra-1/fedex-corporation-loss-submission-form?id=2375&from=1

Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

Topic:
5
Back to newsroom
Back to Newsroom
Share by: